Results for hybridization translation from Maltese to English

minoranza ta’ pazjenti kienu ittestjati bl- użu ta’ fluorescence in-situ hybridization (fish).
a minority of patients were tested using fluorescence in-situ hybridization (fish).

esperjenza f’ pazjenti b’ chb pożittiv għall- hbeag u mard kumpensat tal- fwied: fi studji kontrollati ta 'pazjenti pożittivi għall- hbeag, sena waħda ta' terapija b ’ lamivudine żammet sostanzjalment ir - replikazzjoni ta 'dna tal- hbv {34- 57% ta' pazjenti, kellhom livelli taħt il- limiti li jitkejlu fl- assay (soluzzjoni abbott genostics hybridization assay, llod < 1. 6pg/ ml)}, ġiebet għan- normal il- livell ta 'alt (40- 72% ta' pazjenti), ikkaġunat serokonverżjoni tal- hbeag (telf ta 'dna tal- hbeag u skoperta ta' hbeab b’ telf ta ’ hbv dna [b’ assay konvenzjonali], 16- 18% ta 'pazjenti), tejjbet l- istoloġija (38 - 52% ta' pazjenti kellhom tnaqqis ta ’ ≥ 2 punti fil- knodell histologic activity index [hai]) u naqqset l- avanz ta 'fibrożi (f’ 3- 17% ta ’ pazjenti u l- avanz għaċ- ċirrożi.
experience in patients with hbeag positive chb and compensated liver disease: in controlled studies, 1 year of lamivudine therapy significantly suppressed hbv dna replication (34-57% of patients were below the assay detection limits (abbott genostics solution hybridization assay, llod < 1.6pg/ ml)], normalised alt level (40-72% of patients), induced hbeag seroconversion (hbeag loss and hbeab detection with hbv dna loss [by conventional assay], 16-18% of patients), improved histology (38-52% of patients had a ≥ 2 point decrease in the knodell histologic activity index [hai]) and reduced progression of fibrosis (in 3-17% of patients) and progression to cirrhosis.